Background: Psoriasis is a common long standing immune-related disease that affects 1% - 3% of the general people and is characterized by inflammation and hyperproliferation of epidermal cells. However, Psoriasis has been known to be a systemic disorder related to metabolic syndrome including obesity, insulin resistance, hypertension and atherogenic dyslipidemia. There are higher morbidity and mortality rates in psoriatic patients with atherosclerosis and cardiovascular diseases. Clusterin "apolipoprotein J" plays an important role in metabolic disorders linked with inflammation and oxidative stress such as diabetes, obesity, atherosclerosis and insulin resistance.
Aim of the Work: to compare clusterin levels between psoriatic patients and controls, between patients who have and have no metabolic syndrome and to confine the role of clusterin in disease severity.
Patients and Methods: This study was done on 30 psoriatic patients who have metabolic syndrome, 30 psoriatic patients without metabolic syndrome and 30 sex- and age-matched healthy volunteers as controls. Written consent was signed by each participant before initiation of the study. All patients undergone full history taking, general examination and PASI scoring for psoriasis severity. Serum samples from all participants undergone routine investigations and clusterin levels were determined by ELISA.
Results:clusterin levels showed no difference between patients and controls with no difference in clusterin levels among patients with and without metabolic syndrome.
Conclusion: Based on our results clusterin has no role in psoriasis pathogenesis, in psoriasis comorbidities, clusterin has no role in disease severity and we cannot ensure its role in the mechanism of CV risks with psoriasis.